Letter to the Editor

Patient Approval of Insulin Therapy in Type 2 Diabetic Patients

Authors: Murat Suher, MD, Eyup Koc, MD, Ozlem Barak Serkan, MD

Abstract

The primary goal of therapy in diabetes mellitus is to reach and sustain near-normal glycemic levels to prevent acute metabolic complications.1 When insulin is initiated early in the disease process, this therapy has the potential to preserve β-cell function and delay disease progression.2,3 However, the discomfort and inconvenience of self injection are significant deterrents, to many patients.4

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Rosenstock J, Riddle MC. Insulintherapy in type 2 diabetes. In: Cefalu, WT, Gerich JE, LeRoithD, eds. The CADRE Handbook of Diabetes Management. New York, NY: Medical InformationPress; 2004.
 
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
 
3. Home PD, Boulton AJM, Jimenez J, et al. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diab Int 2003;20:63–71.
 
4. Gardner S, Dunachie SJ, Levy JC. Real gains but practical limitations to glycemic control with insulin in type 2 diabetes. Br J Diabetes Vasc Dis 2004;4:98–102.